Pulse Biosciences Reports 86% Meet Thyroid Nodule Reduction Target in Six-Month Interim Study Results

• Pulse Biosciences reported six-month interim PRECISE-BTN results for its nPulse Vybrance device in 43 patients with benign thyroid nodules.
• Results were presented at the American Thyroid Association annual meeting, held November 4-7, 2026, in Philadelphia.
• Most patients achieved substantial nodule shrinkage, with improvements in symptoms and quality of life.
• No serious adverse events were reported; thyroid hormone levels improved in patients with hyperfunctioning nodules while thyroid function was preserved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261106778880) on November 06, 2026, and is solely responsible for the information contained therein.